BRRGF
BERGENBIO AS by Bergenbio AS (BRRGF)
$50
About BERGENBIO AS by Bergenbio AS (BRRGF)
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. It focuses on developing a pipeline of AXL kinase inhibitors. Its lead product bemcentinib, is a selective and orally bio-available small molecule AXL inhibitor. The company was founded by James Bradley Lorens and David R. Micklem on December 21, 2007 and is headquartered in Bergen, Norway.
Details
Daily high
$2.50
Daily low
$2.50
Price at open
$2.50
52 Week High
$2.50
52 Week Low
$0.02
Market cap
977,200
Dividend yield
0.00%
Volume
0
Avg. volume
0
P/E ratio
-.05
BERGENBIO AS by Bergenbio AS News
Details
Daily high
$2.50
Daily low
$2.50
Price at open
$2.50
52 Week High
$2.50
52 Week Low
$0.02
Market cap
977,200
Dividend yield
0.00%
Volume
0
Avg. volume
0
P/E ratio
-.05